Overview
Waldenström Macroglobulinemia is treated with 1 medication in our database, including BRUKINSA. 1 of these has manufacturer assistance programs available to help reduce out-of-pocket costs. Medications are manufactured by BeiGene. Patients and caregivers can find copay cards, patient assistance programs, and travel grants for Waldenström Macroglobulinemia treatment below.
Multifactorial
Caused by a mix of several genes and environmental factors
Late onset
Begins later in life, typically after age 50
FDA & Trial Timeline
10 eventsMayo Clinic — PHASE1, PHASE2
Centre Hospitalier Universitaire, Amiens — NA
Institute of Hematology & Blood Diseases Hospital, China — PHASE2
French Innovative Leukemia Organisation — PHASE2
Shayna Sarosiek, MD — PHASE2
BeiGene — PHASE4
Institute of Hematology & Blood Diseases Hospital, China — PHASE1
BeOne Medicines — PHASE2
AbbVie — PHASE1
Dana-Farber Cancer Institute — PHASE2
Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
Treatments
2 availableBRUKINSA
BRUKINSA is indicated for the treatment of adult patients with Waldenström's macroglobulinemia (WM).
IMBRUVICA
IMBRUVICA is indicated for the treatment of adult patients with Waldenström's macroglobulinemia (WM).
Rare Disease Specialist
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
1 grantsCommunity
No community posts yet. Be the first to share your experience with Waldenström Macroglobulinemia.
Start the conversation →Latest news about Waldenström Macroglobulinemia
Disease timeline:
New recruiting trial: Loncastuximab Tesirine in WM
A new clinical trial is recruiting patients for Waldenström Macroglobulinemia
New recruiting trial: Spanish Registry of Patients With IgM Monoclonal Gammopathies
A new clinical trial is recruiting patients for Waldenström Macroglobulinemia
New recruiting trial: Pirtobrutinib and Venetoclax in Waldenström Macroglobulinemia
A new clinical trial is recruiting patients for Waldenström Macroglobulinemia
New recruiting trial: Phenotypic and Functional Study of Bone Marrow Mesenchymal Stem Cells in Waldenström Macroglobulinemia
A new clinical trial is recruiting patients for Waldenström Macroglobulinemia
New recruiting trial: Prognostic Value of Circulating Tumoral DNA After the First 6 Months of Treatment in Patients With Waldenström Macroglobulinemia
A new clinical trial is recruiting patients for Waldenström Macroglobulinemia
New recruiting trial: Clinical Study of the Hyperviscosity Syndrome in Waldenström Macroglobulinemia
A new clinical trial is recruiting patients for Waldenström Macroglobulinemia
New recruiting trial: Zanubrutinib, Bendamustine, Rituximab Prev. Untreated WM
A new clinical trial is recruiting patients for Waldenström Macroglobulinemia
New recruiting trial: A Phase 2 Study to Evaluate the Safety and Efficacy of Pacritinib in Relapsed or Refractory Waldenström Macroglobulinemia
A new clinical trial is recruiting patients for Waldenström Macroglobulinemia
New recruiting trial: Observational Study Evaluating the Efficacy and Safety of Zanubrutinib in Participants With Waldenström Macroglobulinemia
A new clinical trial is recruiting patients for Waldenström Macroglobulinemia
New recruiting trial: A Study to Evaluate the Efficacy and Safety of Zanubrutinib in Chinese Adults With Treatment-Naive Waldenström Macroglobulinemia
A new clinical trial is recruiting patients for Waldenström Macroglobulinemia
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Common questions about Waldenström Macroglobulinemia
What is Waldenström Macroglobulinemia?
Waldenström Macroglobulinemia is treated with 1 medication in our database, including BRUKINSA. 1 of these has manufacturer assistance programs available to help reduce out-of-pocket costs. Medications are manufactured by BeiGene. Patients and caregivers can find copay cards, patient assistance programs, and travel grants for Waldenström Macroglobulinemia treatment below.
How is Waldenström Macroglobulinemia inherited?
Waldenström Macroglobulinemia follows a multifactorial inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.
At what age does Waldenström Macroglobulinemia typically begin?
Typical onset of Waldenström Macroglobulinemia is late onset. Age of onset can vary across affected individuals.
Are there clinical trials for Waldenström Macroglobulinemia?
Yes — 9 recruiting clinical trials are currently listed for Waldenström Macroglobulinemia on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.
Which specialists treat Waldenström Macroglobulinemia?
24 specialists and care centers treating Waldenström Macroglobulinemia are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.
What treatment and support options exist for Waldenström Macroglobulinemia?
1 FDA-approved treatment are currently tracked on UniteRare for Waldenström Macroglobulinemia. See the treatments and support programs sections for copay assistance, eligibility, and contact details.